Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2023 – 2024

Nightingale Health Plc, Company release, 31 May 2023 at 9:30 a.m. (EEST)

During financial year 1 July 2023 – 30 June 2024, Nightingale Health Plc will release its financial reports as follows:

• Financial Statements Release for 1 July 2022 – 30 June 2023 on Thursday, 28 September 2023
• Half-year Financial Report for 1 July – 31 December 2023 on Thursday, 7 March 2024
• Annual Report 2022 – 2023 will be published during week 42/2023.

Nightingale Health’s Annual General Meeting 2023 will be held on Thursday, 16 November 2023. The Board of Directors will convene the meeting at a later date.

More information on the events of the financial year will be available on the company’s investor pages at https://nightingalehealth.com/investors.

For further information, please contact:

Teemu Suna, CEO

ir[at]nightingalehealth.com

Certified Adviser:

Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com

Tags: